GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Inclusion Criteria: * Males and females 18-70 years of age * Chronic HCV infection * Subjects must have liver biopsy results (≤ 3 years prior to screening) indicating the absence of cirrhosis. Alternatively a non-invasive alternative to liver biopsy (such as FibroTest, FibroScan, or Acoustic Radiation Force Impulse imaging) within 6 months of Screening in countries where allowed * Monoinfection with HCV genotype 1a or 1b * HCV RNA \> 10\^4 IU/mL at Screening * IL28B CC genotype * HCV treatment naïve * Candidate for PEG/RBV therapy * Body mass index (BMI) between 18 and 36 kg/m2 * Creatinine clearance \>= 50 mL/min * Agree to use two forms of highly effective contraception methods for the duration of the study and for 7 months after the last dose study medication. Females of childbearing potential must have negative pregnancy test at Screening and Baseline Exclusion Criteria: * Exceed defined thresholds for key laboratory parameters at Screening * Diagnosis of autoimmune disease, decompensated liver disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), HIV, hepatitis B virus (HBV), hepatocellular carcinoma or other malignancy (with exception of certain skin cancers), hemoglobinopathy, retinal disease, or are immunosuppressed * Subjects with current use of amphetamines, cocaine, opiates (e.g., morphine, heroin), or ongoing alcohol abuse are excluded. Subjects on stable methadone maintenance treatment for at least 6 months prior to Screening may be included into the study * Use of prohibited concomitant medications two weeks prior to baseline through the end of treatment